Electronic ISSN 2287-0237

VOLUME

UPDATE ON MIGRAINE PROPHYLAXIS: THINGS THAT CAN HELP YOUR MIGRAINE PATIENTS

FEBRUARY 2013 - VOL.5 | REVIEWS ARTICLE
  1. Lipton RB, Bigal ME, Diamond M, et al, for the AMPP Advisory Group. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology  2007; 68:343-9.
  2. Lipton RB, Stewart WF, Diamond S, et al. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache  2001;41:646-57.
  3. Ferrari MD. The economic burden of migraine to society.Pharmacoeconomics 1998;13:667-76.
  4. Stewart WF, Lipton RB, Simon D. Work-related disability: results from the American Migraine study. Cephalalgia 1996;16:231-8.
  5. Michel P, Dartigues JF, Lindousli A, et al. Loss of produc- tivity and quality of life in migraineurs among French workers: results from the GAZEL cohort. Headache 1997;37:71-8.
  6. Headache Classification Committee of the International Headache Society, The International Classification of Headache Disorders: 2nd edition, Cephalalgia 2004;24 (Suppl 1):9-160.
  7. Schoenen J. Neurophysiological features of the migrainous brain. Neurol Sci 2006;27:77-81.
  8. Olesen J, Burstein R, Ashina M, et al. Origin of pain in migraine: evidence for peripheral sensitisation. Lancet Neurol 2009; 8:679-90.
  9. Maizels M, Aurora S, Heinricher M. Beyond Neurovas- cular: Migraine as a Dysfunctional Neurolimbic Pain Network. Headache 2012 Jul 3. doi: 10.1111/j.1526-4610. 2012.02209.x. [Epub ahead of print]
  10. Mainero C, Boshyan J, Hadjikhani N. Altered functional magnetic resonance imaging  resting-state  connectivity in periaqueductal gray networks in migraine. Ann Neurol 2011;70:838-45.
  11. Leonardi M, Steiner TJ, Scher AI, et al. The global burden of migraine: measuring disability in headache disorders with WHO’s Classification of Functioning, Disability and Health (ICF). J Headache and Pain 2005; 6:429-40.
  12. Stovner Lj, Hagen K, Jensen R, et al. The global burden of headache: a documentation of headache prevalence and disability worldwide. Cephalalgia  2007;27:193-210.
  13. Edmeads J, Mackell JA. The economic impact of migraine: an analysis of direct and indirect costs. Headache 2002;42:501-9.
  14. Ferrari MD. The economic burden of migraine to society.Pharmacoeconomics 1998;13:667-76.
  15. Stewart WF, Lipton RB, Simon D. Work-related disability: results from the American Migraine study. Cephalalgia 1996;16:231-8.
  16. Michel P, Dartigues JF, Lindousli A, et al. Loss of produc- tivity and quality of life in migraineurs among French workers: results from the GAZEL cohort. Headache 1997;37:71-8.
  17. Silberstein SD, Winner PK, Chmiel JJ. Migraine preventive medication reduces resource utilization. Headache 2003;43:171-8.
  18. Silberstein SD. Preventive treatment of migraine: an overview. Cephalalgia  1997;17:67-72.
  19. Brown JS, Papadopoulos G, Neumann PJ, et al. Cost-effectiveness of topiramate in migraine prevention: Results from a pharmacoeconomic model of topiramate treatment. Headache  2005;45:1012-22.
  20. D’Amico D, Solari A, Usai S, et al. Improvement in quality of life and activity limitations in migraine patients after prophylaxis. A prospective longitudi- nal multicentre study. Cephalalgia  2006;26:691-6.
  21. Silberstein SD, for the US Headache Consortium Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000;55:754-62.
  22. Silberstein SD, Rosenberg J. Multispecialty consensus on diagnosis and treatment of headache. Neurology 2000;54: 1553.
  23. Schroeder BM. AAFP/ACP-ASIM release guidelines on the management and prevention of migraines. Am Fam Physician 2003;67:1392,1395-7.
  24. Evers S, Afra J, Frese A, et al. European Federation of Neurological Societies. EFNS guideline on the drug treatment of migraine--revised report of an EFNS task force. Eur J Neurol  2009;16:968-81.
  25. Bigal ME, Lipton RB. Migraine chronification. Curr Neurol Neurosci Rep 2011;11(2):139-48.
  26. Evans RW, Loder E, Biondi DM. When can successful migraine prophylaxis be discontinued? Headache 2004; 44:1040-2.
  27. Lipton RB. Tracing transformation:chronic migraine classification,progression, and epidemiology.Neurology 2009;72(Suppl 5):S3-7.
  28. Bigal ME, Serrano D, Buse D, et al. Acute migraine medications and evolution from episodic to chronic migraine: a longitudinal population-based study. Headache 2008;48:1157-68.
  29. Bigal ME, Lipton RB, Holland PR, et al. Obesity, migraine, and chronic migraine: possible mechanisms of interaction. Neurology 2007;68:1851-61.
  30. Scher AI, Lipton  RB,  Stewart  WF.  Habitual  snoring  as a risk factor for chronic daily headache. Neurology 2003;60:1366-8.
  31. Scher AI, Stewart WF, Buse D, et al. Major life changes before and after the onset of chronic daily headache: a population-based study. Cephalalgia  2008;28:868-76.
  32. Silberstein SD, Holland S, Freitag F, et al. Quality Standards  Subcommittee  of   the  American  Academy of Neurology and the American Headache Society. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology 2012;78:1337-45.
  33. Holland S, Silberstein SD, Freitag F, et al. Quality Standards  Subcommittee  of   the  American  Academy of Neurology and the American Headache Society. Evidence-based guideline update: NSAIDs and other complementary treatments for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology 2012;78: 1346-53.
  34. Mulleners WM, Chronicle EP. Anticonvulsants in migraine prophylaxis: a Cochrane review. Cephalalgia 2008;28: 585-97.
  35. Dodgson SJ, Shank RP, Maryanoff BE. Topiramate as an inhibitor of carbonic anhydrase isoenzymes. Epilepsia 2000;41(Suppl 1):S35-9.
  36. Andreou AP, Goadsby PJ. Topiramate in the treatment of migraine: a kainate (glutamate) receptor antagonist within the trigeminothalamic pathway. Cephalalgia 2011;31: 1343-58.
  37. Schürks M, Diener HC, Goadsby P. Update on the prophylaxis of migraine. Curr Treat Options Neurol 2008; 10:20-9.
  38. Pringsheim T, Davenport WJ, Becker WJ. Prophylaxis of migraine headache. CMAJ 2010;182:E269-76.
  39. Barbanti P, Aurilia C, Egeo G, et al. Migraine prophylaxis: what is new and what we need? Neurol Sci 2011;32 (Suppl 1):S111-5.
  40. Margulis AV, Mitchell AA, Gilboa SM, et al. National Birth  Defects  Prevention  Study.   Use   of   topiramate in pregnancy and risk of oral clefts. Am J Obstet Gynecol 2012;207:405.e1-7.
  41. Abtahi MA, Abtahi SH, Fazel F, et al. Topiramate and the vision: a systematic review. Clin Ophthalmol 2012;6: 117-31.
  42. Vikelis M, Rapoport AM. Role of antiepileptic drugs as preventive agents for migraine. CNS Drugs 2010;24: 21-33.
  43. Silberstein SD, Wilmore LJ. Divalproex sodium: migraine treatment and monitoring. Headache 1996;36:239-42.
  44. Galletti F, Cupini LM, Corbelli I, et al. Pathophysiological basis of migraine prophylaxis. Prog Neurobiol 2009;89: 176-92.
  45. Linde K, Rossnagel K. Propranolol for migraine prophy- laxis. Cochrane Database Syst Rev 2004;CD003225.
  46. Diener HC, Matias-Guiu J, Hartung E, et al. Efficacy  and tolerability in migraine  prophylaxis  of  flunarizine in reduced doses: a comparison with propranolol 160 mg daily. Cephalalgia  2002;22:209-21.
  47. Leone M, Grazzi L, Mantia LL, et al. Flunarizine in migraine: a mini review. Headache 1991;31: 388-91.
  48. Diener H, Matias-Guiu J, Hartung E, et al. Efficacy and tolerability in migraine prophylaxis of flunarizine in reduced doses: a comparison with propranolol 160 mg daily. Cephalalgia  2002;22:209-21.
  49. Reveiz-Herault L, Cardona AF, Ospina EG, et al. Effec- tiveness of flunarizine in the prophylaxis of migraine: a meta-analytical review of the literature. Rev Neurol 2003;36:907-12.
  50. Jackson JL, Shimeall W, Sessums L, et al. Tricyclic antidepressants and headaches: systematic review and meta-analysis. BMJ  2010;341:c5222.
  51. Couch JR. Amitriptyline Versus Placebo Study Group. Amitriptyline in the prophylactic treatment of migraine and chronic daily headache. Headache 2011;51:33-51.
  52. Ozyalcin SN, Talu GK, Kiziltan E, et al. The efficacy and safety of venlafaxine in the prophylaxis of migraine. Headache 2005;45:144-52.
  53. Milla´n-Guerrero RO, Isais-Milla´n R, Benjamín TH, et al. N-alpha-methyl histamine safety and efficacy in migraine prophylaxis: phase III study. Can J Neurol Sci 2006;33:195-9.
  54. Milla´n-Guerrero RO, Isais-Milla´n R, Barreto-Vizcaíno S, et al. Subcutaneous histamine versus sodium valproate in migraine prophylaxis: a randomized, controlled, doubleblind study. Eur J Neurol 2007;14:1079-84.
  55. Milla´n-Guerrero RO, Isais-Milla´n R, Barreto-Vizcaíno S,  et  al.  Subcutaneous  histamine  versus  topiramate   in migraine prophylaxis: a double-blind study. Eur Neurol 2008;59:237-42.
  56. Rao BS, Das DG, Taraknath VR, et al. A double blind controlled study of propranolol and cyproheptadine in migraine prophylaxis. Neurol India 2000;48:223-6.
  57. Welch KMA: Naproxen sodium in the treatment of migraine. Cephalalgia 1986;6:85-92.
  58. Diener HC, Hartung E, Chrubasik J, et al. A comparative study of acetylsalicyclic acid and metoprolol for the prophylactic treatment of migraine. A randomised, controlled, double-blind, parallel group phase III study. Cephalalgia  2001;21:140-4.
  59. Benseñor IM, Cook NR, Lee IM, et al. Low-dose aspirin for migraine prophylaxis in women.Cephalalgia    2001;21: 175-83.
  60. Schrader H, Stovner LJ, Helde G, et al. Prophylactic treatment of migraine with angiotensin converting enzyme inhibitor (lisinopril): randomised, placebo controlled, crossover study. BMJ 2001;322:19-22.
  61. Tronvik E, Stovner L, Helde G, et al. Prophylactic treatment of migraine with an angiotensin II receptor blocker: a randomized controlled trial. JAMA 2003;289: 65-9.
  62. Grossman W, Schmidramsl H. An extract of Petasites hybridus is effective in the prophylaxis of migraine. Altern Med Rev 2001;6:303-10.
  63. Lipton RB, Gobel H, Einhaupl KM, et al. Petasites hybridus root (butterbur) is an effective preven-tive treatment for migraine. Neurology 2004;63:2240-4.
  64. Pfaffenrath V, Diener HC, Fischer M, et al. The efficacy and safety of Tanacetum parthenium (feverfew) in migraine prophylaxis–a double-blind, multicentre, randomized placebo- controlled dose-response study. Cephalalgia 2002;22:523-32.
  65. Diener HC, Pfaffenrath V, Schnitker J, et  al.  Efficacy and safety of 6.25 mg tid feverfew CO2-extract (MIG-99) in migraine prevention–a randomized, double-blind, multicentre, placebo-controlled study. Cephalalgia 2005; 25:1031-41.
  66. Watanabe H, Kuwabara T, Ohkubo M, et al. Elevation  of cerebral lactate detected by localized 1H-magnetic resonance spectroscopy in migraine during the interictal period. Neurology 1996;47:1093-5.
  67. Penn AMW, Lee JWK, Thuillier P, et al. MELAS syndrome with mitochondrial tRNALeu (UUR) mutation: correlation of clinical state, nerve conduction, and muscle 31P magnetic resonance spectroscopy during treatment with nicotinamide and riboflavin. Neurology 1992;42: 2147-52.
  68. Nishikawa Y, Takahashi M, Yorifuji S, et al. Long-term coenzyme Q10 therapy for a mitochondrial encephalomy- opathy with cytochrome c oxidase deficiency: a 31P NMR study. Neurology 1989;39:399-403.
  69. Montagna P. High-dose riboflavin as a prophylactic treatment. Cephalalgia 1994;14:317.
  70. Schoenen J, Jacquy J, Lenaerts M. Effectiveness of high-dose riboflavin in migraine prophylaxis. A randomized controlled trial. Neurology  1998;50:466-70.
  71. Peikert A, Wilimzig C, Köhne-Volland  R.  Prophylaxis of migraine with oral magnesium: results from a prospective, multi-center, placebo-controlled and double-blind randomized study. Cephalalgia 1996;16: 257-63.
  72. Maizels M, Blumenfeld A, Burchette R. A combination of riboflavin, magnesium, and feverfew for migraine prophylaxis: a randomized trial. Headache 2004;44: 885-90.
  73. Hershey AD, Powers SW, Vockell A-LB, et al. Coenzyme Q10 deficiency and response to supplementation in pediatric and adolescent migraine. Headache 2007;47: 73-80.
  74. Rozen TD, Oshinsky ML, Gebeline CA, et al.  Open label trial of coenzyme Q10 as a migraine preventive. Cephalalgia  2002;22:137-41.
  75. Sándor PS, Di Clemente L, Coppola G, et al. Efficacy   of coenzyme Q10 in migraine prophylaxis: a randomized controlled trial. Neurology 2005;64:713-5.
  76. Simpson LL.The origin,structure,and pharmacological activity of botulinum toxin.Pharmacol Rev1981;33:155-88.
  77. Cui M, Khanijou S, Rubino J, et al. Subcutaneous administration of botulinum toxin A reduces formalin-induced pain. Pain  2004;107(1-2):125-33.
  78. Aoki KR. Review  of  a  proposed  mechanism  for the antinociceptive action of botulinum toxin type A. Neurotoxicology 2005;26(5):785-93.
  79. Olesen J, Bousser MG, Diener HC, et al. New appendix criteria open for a broader concept of chronic migraine. Cephalalgia 2006;26:742-6.
  80. Aurora SK, Dodick DW, Turkel CC, et al. PREEMPT 1 Chronic Migraine Study Group. OnabotulinumtoxinA  for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia 2010;30:793-803.
  81. Diener HC, Dodick DW, Aurora SK, et al. PREEMPT 2 Chronic Migraine Study Group. OnabotulinumtoxinA  for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia  2010;30:804-14.
  82. Dodick DW, Turkel CC, DeGryse RE, et a. PREEMPT Chronic Migraine Study Group. OnabotulinumtoxinA  for treatment of chronic migraine: pooled results from  the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache 2010;50: 921-36.
  83. Aurora SK, Winner P, Freeman MC, et al. Onabotu- linumtoxinA for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program. Headache  2011;51:1358-73.
  84. Sandrini G, Perrotta A, Tassorelli C, et al. Botulinum tox in type-A in the prophylactic treatment of medication-overuse| headache: a multicenter, double-blind, randomized, placebo-controlled, parallel group study. J Headache Pain 2011;12:427-33.
  85. Stensrud P, Skaug OE, Sjaastad O. Clinical trial of MY-25 (1-methyl-ergotamine-bitartrate) in migraine prophylaxis. Headache 1971;11:128-31.
  86. Kallanranta T, Hakkarainen H, Hokkanen E, et al.Clonidine in migraine prophylaxis. Headache 1977;17: 169-72.
  87. Martin VT. Menstrual migraine: a review of prophylactic therapies. Curr Pain Headache Rep 2004;8:229-37.
  88. Sances G, Martignoni E, Fioroni L, et al. Naproxen sodium in menstrual migraine prophylaxis: a double-blind placebo controlled study. Headache 1990;30:705-9.
  89. Sullivan E, Bushnell C. Management of menstrual migraine: a review of current abortive and prophylactic therapies. Curr Pain Headache Rep 2010;14:376-84.
  90. Pringsheim T, Davenport WJ, Dodick D. Acute treatment and prevention of menstrually related migraine headache: evidence-based review. Neurology 2008 22;70:1555-63.
SEARCH VOLUME & NUMBER
GO
RECENT VOLUME & NUMBER